Skip to content
Open access

Treatment-Limiting Taxane-Induced Peripheral Neuropathy: Timing, Severity and Clinical Predictors in Patients Receiving Neoadjuvant TCHP.

Sep 2026 · Maedica · Vol 21 3, pp. 595-601 · 0 citations
Medicine

Abstract

Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common and clinically significant neurotoxicity associated with taxane-based chemotherapy, which is frequently leading to treatment modification or discontinuation. In the neoadjuvant setting, treatment-limiting CIPN may compromise the delivery of planned therapy. However, detailed data on the timing, severity and clinical predictors of severe CIPN remain limited, particularly in real-world populations. Methods We conducted a retrospective single-institution cohort study including consecutive patients with HER2-positive breast cancer treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP). The analysis was restricted to patients who developed CIPN requiring discontinuation of docetaxel. Neuropathy severity was graded according to CTCAE v6.0 and categorized as grade 2 or grade 3. Clinical variables associated with severe neuropathy were evaluated using Firth penalized logistic regression. Results Among 843 patients treated with neoadjuvant TCHP, 180 (21.4%) developed treatment-limiting CIPN and were included in the analysis. Grade 3 neuropathy occurred in 32 patients (17.8%). Severe CIPN was associated with higher body mass index, diabetes mellitus, pre-existing peripheral neuropathy and cardiovascular comorbidities. Neuropathy frequently developed early during treatment, with a substantial proportion of severe cases occurring within the first two cycles or present at baseline. Patients with grade 3 CIPN received fewer cycles of chemotherapy, reflecting early treatment discontinuation. Conclusions Treatment-limiting CIPN during neoadjuvant taxane-based therapy is often an early event and is strongly associated with patient-related vulnerability factors, particularly metabolic and neurologic comorbidities. These findings support the need for early risk stratification and closer neurologic monitoring in patients at increased risk for severe neurotoxicity.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.